PDCD1 and neoplasm: Unlike other models where concurrent blockade of PD-1 and TIM-3 delays tumour progression as initial therapy in the context of high expression levels of these checkpoints24, we observed no additional benefit of combination therapy as initial therapy as compared with anti-PD-1 alone (Supplementary Fig. 6a,b).